FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...

Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...

CHICAGO — June 5, 2017 — For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life ...

The Lancet study shows addition of bortezomib significantly improves survival in treatment-naïve patients with multiple myeloma. In treatment-naïve patients with multiple myeloma, including ...

SWOG Clinical Trials Partnerships (SWOG CTP) has signed a collaborative research agreement with Novartis Pharmaceuticals Corporation to form a strategic alliance via our Preferred Partnership Program ...

Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort Secondary analyses from CALGB/SWOG 80405 provide insight into treatment paradigms for patients ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added toxicity MOUNTAIN VIEW, Calif., January 08, 2026--(BUSINESS WIRE)--Osel Inc., a ...

Investigators analyzed OS and PFS for patients with follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/ prednisolone (CHOP ...

For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life for cancer patients in ...